Get the latest news on Capital Environment stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on CPEVF performance

Latest Capital Environment Stock News | OTC:CPEVF | Benzinga

Capital Environment Holdings Ltd is an investment holding company engaged in the provision of waste treatment technologies and services, which specializes in technology development, design, system integration, project investment, consultancy, operation, and maintenance of waste treatment facilities, especially waste-to-energy projects. The Group has a single reportable segment which is the Waste treatment & waste-to-energy business in the PRC.

CAPITAL ENVIRONMENT ORD by Capital Environment Holdings Ltd

Capital Environment Holdings Ltd

Nautilus Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAUT#NASDAQ">NAUT</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is unchanged from the same period last year.

Earnings

Earnings Beats

News

NAUT

Nautilus Biotechnology Q4 GAAP EPS $(0.14) Beats $(0.16) Estimate

Thryv Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRY#NASDAQ">THRY</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $(0.12) by 258.33 percent. This is a 40.63 percent decrease over earnings of $0.32 per share from the same period last year. The company reported quarterly sales of $186.60 million which beat the analyst consensus estimate of $183.02 million by 1.95 percent. This is a 20.99 percent decrease over sales of $236.16 million the same period last year.

THRY

Thryv Holdings Q4 EPS $0.19 Beats $(0.12) Estimate, Sales $186.60M Beat $183.02M Estimate

Baird analyst Peter Benedict maintains Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) with a Outperform and raises the price target from $12 to $13.

Price Target

Analyst Ratings

ARHS

Baird Maintains Outperform on Arhaus, Raises Price Target to $13

Needham analyst Chris Pierce reiterates Joby Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) with a Buy and maintains $10 price target.

Reiteration

JOBY

Needham Reiterates Buy on Joby Aviation, Maintains $10 Price Target

Biotech

General

QNRX

Quoin Pharmaceuticals Announces Whole Body' Data From Ongoing Pediatric Netherton Syndrome Study; Says Both Key Clinical Endpoints Demonstrated Significant Clinical Improvements From Baseline After Two Weeks Of Treatment With QRX003

Full-Year 2025 Outlook
<ul>
<li>Revenue range of $2.0 billion to $2.04 billion</li>
<li>Gross profit margin range of 51.5% to 53%</li>
<li>Adjusted EBITDA(2) range of $450 million to $475 million</li>
</ul>

Guidance

FTDR

Frontdoor 2025 Outlook: Expects Revenue Of $2B-$2.04B Vs. $1.943B Est.; Sees Adjusted EBITDA Between $450M-$475M And Gross Margin 51.5%-53%

Rosenblatt analyst Kevin Cassidy maintains Innoviz Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVZ#NASDAQ">INVZ</a>) with a Buy and maintains $4 price target.

INVZ

Rosenblatt Maintains Buy on Innoviz Technologies, Maintains $4 Price Target

Needham analyst Mike Cikos reiterates Pure Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) with a Buy and maintains $75 price target.

PSTG

Needham Reiterates Buy on Pure Storage, Maintains $75 Price Target

Cars.com (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARS#NYSE">CARS</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.14 by 250 percent. The company reported quarterly sales of $180.43 million which missed the analyst consensus estimate of $183.90 million by 1.88 percent. This is a 0.46 percent increase over sales of $179.61 million the same period last year.

Earnings Misses

CARS

Cars.com Q4 2024 Adj EPS $0.49 Beats $0.14 Estimate, Sales $180.43M Miss $183.90M Estimate

2025 guidance is as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">$1,040 million - $1,050 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Transaction costs</td>
<td colspan="1" rowspan="1">~18.0% of revenue</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Adjusted EBITDA (1)</td>
<td colspan="1" rowspan="1">$255 million to $265 million</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

PAYO

Payoneer Global Expects FY25 Revenue Of $1.04B-$1.05B Vs $1.035B Est

WIIM

ZVRA

Zevra Therapeutics shares are trading higher after the company announced it will sell its Pediatric Disease Priority Review Voucher for gross proceeds of $150 million.

Mizuho analyst Ben Chaiken maintains United Parks &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRKS#NYSE">PRKS</a>) with a Underperform and raises the price target from $43 to $45.

PRKS

Mizuho Maintains Underperform on United Parks & Resorts, Raises Price Target to $45

Cronos Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) reported quarterly sales of $30.30 million which missed the analyst consensus estimate of $34.95 million by 13.29 percent. This is a 26.70 percent increase over sales of $23.91 million the same period last year.

CRON

Cronos Group Q4 Sales $30.30M Miss $34.95M Estimate

Full Year 2025 Outlook
<ul>
<li>The Company expects full-year 2025 Adjusted EBITDA attributable to stockholders excluding deferrals and recognitions to be in a range of $1.125 billion to $1.165 billion.
<ul>
<li>Guidance includes an estimated $25 million of incremental consumer financing interest expense attributable to a planned increase in non-recourse borrowing activity associated with the Company's Financing Business Optimization, as detailed below.</li>
<li>The Company intends to increase its average quarterly share repurchase goal to $150 million per quarter, from the current $100 million per quarter, to take advantage of the increased cash generated from its Financing Business Optimization program, and will continue to evaluate its share repurchase strategy with its Board of Directors on a routine basis.</li>
</ul>
</li>
</ul>

Hilton Grand Vacations FY25 Adjusted EBITDA Outlook $1.125B-$1.165B

Frontdoor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTDR#NASDAQ">FTDR</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.11 by 145.45 percent. This is a 35 percent increase over earnings of $0.20 per share from the same period last year. The company reported quarterly sales of $383.00 million which beat the analyst consensus estimate of $367.91 million by 4.10 percent. This is a 4.64 percent increase over sales of $366.00 million the same period last year.

Frontdoor Q4 2024 Adj EPS $0.27 Beats $0.11 Estimate, Sales $383.00M Beat $367.91M Estimate

Needham analyst David Saxon reiterates Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) with a Buy and maintains $16 price target.

ATEC

Needham Reiterates Buy on Alphatec Holdings, Maintains $16 Price Target

Asset Sales

Zevra Therapeutics To Sell Its Pediatric Disease Priority Review Voucher For Gross Proceeds Of $150M

Installed Building Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBP#NYSE">IBP</a>) reported quarterly earnings of $2.88 per share which beat the analyst consensus estimate of $2.85 by 1.05 percent. This is a 5.88 percent increase over earnings of $2.72 per share from the same period last year. The company reported quarterly sales of $750.20 million which missed the analyst consensus estimate of $762.95 million by 1.67 percent. This is a 4.09 percent increase over sales of $720.70 million the same period last year.

Installed Building Prods Q4 2024 Adj EPS $2.88 Beats $2.85 Estimate, Sales $750.20M Miss $762.95M Estimate

Rosenblatt analyst Mike Genovese maintains Applied Optoelectronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) with a Buy and lowers the price target from $44 to $36.

AAOI

Rosenblatt Maintains Buy on Applied Optoelectronics, Lowers Price Target to $36

Fourth quarter of 2024 highlights1
<ul>
<li>Total contract sales were $837 million.</li>
<li>Member count was 724,000. Consolidated Net Owner Growth (NOG) for the year ended Dec. 31, 2024, was 1.1%.</li>
</ul>

Comments

Capital Environment Stock News

News

Latest Capital Environment Stock News | OTC:CPEVF | Benzinga

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga